Eileen Sawyer

Eileen Sawyer

Company: uniQure, Inc

Job title: Vice President, Global Medical Affairs


Eileen Sawyer joined uniQure in 2016, where she serves as Vice President and Head of Medical Affairs, leading uniQure’s medical affairs activities across the portfolio with a focus on supporting the hemophilia B gene therapy program. Prior to joining uniQure, she spent 3 years at Alexion Pharmaceuticals where she served as the scientific communications lead for the launch of asfotase alfa (Strensiq), an enzyme replacement for a rare metabolic disease. Eileen earned her PhD in Neuroscience from Emory University in 2011 and conducted her post-doctoral training in preclinical drug discovery at Harvard University prior to transitioning to industry.


Live Presenter Q&A 10:10 am

Read more

day: Day One

A Patient-Centric Approach to Drug Development Across the Lifecycle 8:50 am

• Incorporating patient perspectives and how to involve patients in gene therapy drug development • At what stage of the program lifecycle should patients be involved in order to meet their needs and to optimize trial conduct • How to provide a compelling value proposition for multiple stakeholdersRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.